Publish in this journal
Journal Information
Vol. 8. Issue 4.
Pages 163-167 (July - August 2012)
Visits
...
Vol. 8. Issue 4.
Pages 163-167 (July - August 2012)
Editorial
DOI: 10.1016/j.reumae.2012.06.010
Full text access
Should We Use Poor Prognosis Factors to Start Early Treatment in Patients With Rheumatoid Arthritis?
¿Debemos usar los factores de mal pronóstico para iniciar precozmente un tratamiento biológico en los pacientes con artritis reumatoide?
Visits
...
Lara Valor??
Corresponding author
lvalor.hgugm@salud.madrid.org

Corresponding author.
, Inmaculada de la Torre Ortega
Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
Rheumatoid Arthritis: Current Problems

Treatment of rheumatoid arthritis (RA) has undergone a radical change in recent years by optimization not only of classical treatments with disease modifying drugs and the introduction of new biological therapies,1–8 but also of the objectives (treat to target) in the short- and long-terms in monitoring and standardization of patients and procedures.9

It is increasingly evident that there is a window of opportunity period in which, after the diagnosis, the use of more effective therapies and established pretreatment objectives lead to improved long-term prognosis.9,10 In this sense, the proposed new referral and classification11 criteria for RA12 allow this therapeutic approach to be started early. Studies show that in the first two years of treatment any well-considered strategy may induce remission.13,14 What is more controversial is whether long-term strategies based on non-biological agents compared to early introduction of biological drugs, maintain a prolonged remission avoiding further progression of radiologic damage15,16 or disability.17 In this regard, results from trials using biological anti-TNF-alpha drugs in patients with RA cohorts of established RA patients show that active treatment and early introduction of biologic therapies are critical to the achievement of long term therapeutic objectives.18–21

The reality in our clinical practice is that despite the biological treatment, a proportion of patients with inflammatory activity persist or present radiological progression.22 The question remains whether therapy may be optimized in these patients. Recent publications such as Aletaha et al.23 warn about the importance of the persistence of swollen joints, rather than high values of C-reactive protein (CRP) as a determinant of long-term radiographic progression. It has shown a direct relationship between increases in DAS28, where the number of swollen joints is one of the parameters to take into account (28 Joints Disease Activity Score) and loss of function measured by Health Assessment Questionnaire (HAQ).24

Although referral criteria remain relatively arbitrary, with the introduction of the Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) indices there is advancement in trying to find a standardized way of assessing clinical remission in our patients25–27; unfortunately they still do not integrate important aspects such as radiological progression, extra-articular manifestations and development of comorbidities of patients.

So far the treatment of RA has been “arbitrarily homogeneous,” with strategies that could be called step-up, from “more profitable” drugs and with longer time of use, to more sophisticated therapeutic strategies including non-biological and biological drug combinations,28 knowing that there are significant differences in the clinical prognosis of patients. It is not surprising therefore that absolute remission is achieved and maintained in only 30%, irrespective29 of the therapy employed. This gives us an idea of the heterogeneity of patients with RA and the importance of clinically classifying at least those with an increased risk of progressive damage, as we move forward in understanding the pathogenesis of RA, which allows a more personalized medicine.

Historically we have used rheumatoid factor (RF) in the diagnosis of RA,30 but since the discovery of antibodies to citrullinated proteins and the development of Enzyme Linked Immunosorbent Assay (ELISA) commercial kits for antibodies to citrullinated peptides (anti-CCP), we have seen an increase in the diagnosis of RA and improvements in the prognosis of patients. There is more and more talk of “anti-CCP positive vs. anti-CCP negative patients”.30,31 The sensitivity of anti-CCP and its relationship to radiological progression and extraarticular damage has been demonstrated in several registries.32–35 In RA patients the concentration of anti-CCP antibodies was higher in synovial fluid than in blood, suggesting that they may be produced in the swollen synovial membrane itself.36,37 One might argue whether the production of antibodies against citrullinated proteins is a consequence of chronic synovial inflammation, or one of the factors that trigger it.

It should also be noted that although the presence of the protein tyrosine phosphatase, non-receptor type 22-lymphoid (PTNP22) shared epitope and other non-genetic determinants are both related to the evolution of the disease,38 they do so due to the ability that these patients have to generate antibodies against proteins that are physiologically citrulinated.39

Antibodies to Citrullinated Proteins: Etiopathogenic Implications in Rheumatoid Arthritis

The posttranslational citrullination is a phenomenon consisting in transforming the essential amino acid arginine to the non essential amino acid citruline,40 a process catalyzed by the calcium-dependent enzyme peptidyl-arginine deaminase (PAD). It occurs physiologically in the process of keratinization, chemotaxis, inflammation, trauma, aging, neuronal growth, embryonic development and apoptosis.41–49 So far 5 isoforms of PAD (PAD-1, 2, 3, 4, and 6) have been described and there are PAD isoforms-2 and PAD-4 which have been demonstrated in joint structures and have been linked to the pathophysiology of RA.50 Yet the mechanism by which a physiological process becomes pathological, triggering an immune response against autoantigens formed de novo in the context of RA is unknown. Is it the size or type of immune response against these antigens? Is a specific cellular and humoral microenvironment with a genetic predisposition associated with HLA favoring an abnormal pattern of response?

It is known that central and peripheral tolerance against autoantigens at certain checkpoints (bone marrow and secondary lymphoid organs) is impaired in autoimmune diseases, leading inevitably to self-reactive B cells, which should not circulate in peripheral blood, but which are able to complete their normal development and maturation with the consequent possible production of autoantibodies. Samuels et al.51 postulated that this alteration could be developed in the early stages of the evolutionary cycle of the B cell, at the time of assembly of the V (D) J fragments of the BCR (B-cell receptor),52–54 and it would explain the existence of a long latency period, even over several years (between 1.5 and 9), between the determination of anti-CCP antibodies in patients with undifferentiated arthritis until they meet the criteria for RA of the American College of Rheumatology (ACR).55

Anti-CCP antibodies were detected and first described in 1964 as a “perinuclear anti-factor” antibody by Nienhuis and Mandema,56 and then by Young et al. as an anti keratin antibody using as substrate rat57 esophagus. Although subsequent studies demonstrated a high specificity of these antibodies in RA patients, standardization for their detection is extremely complex and was not achieved until 1995 when two antibodies against filial elements of the same group, both directed against filaggrin, a protein constituent of epithelial cells epiteliales58 were described.

These antibodies have been detected in other clinical conditions such as psoriasis, juvenile idiopathic arthritis (JIA), multiple sclerosis, RA, Alzheimer's disease and various cancers, all linked to the presence of PAD enzymes and with a citrullinated substrate sensitivity and specificity different from those reached in RA.59–63

Commercial assays used in routine laboratories detect the presence of immunoglobulin G (IgG) antibodies by ELISA. Specifically in patients with RA, it has been shown that anti-CCP antibodies are produced in response to antigenic stimulation triggered by proteins such as filaggrin, fibrinogen or the residue of vimentin,64,65 and all are present in both the liquid and synovial tissue and which are likely to be citrullinated.66,67 In hindsight, other stimulant antigen in murine and humans have swollen the list, such as citrullinated α-enolase and type II collagen (C1).68,69 However, despite numerous studies carried out, we have not yet have a well defined spectrum of antigenic determinants that induce this type of immune response in the context of the pathophysiology of RA. Scientific evidence suggests that the protein-substrate epitopes that can be citrullinated in RA are able to efficiently induce antikeratin antiperinuclear types, antivimentin/Sa and antifibrinogen citrullinated autoantigenic antibodies, and occur early in the progression of RA, besides being more specific than RF.70

The detection of anti-CCP has demonstrated a high specificity and sensitivity, high predictive value and cost-effectiveness and provided a key tool for the diagnosis and treatment implementation for early-onset RA. Although routine measurements focus on the detection of IgG anti-CCP, IgM and IgA in RA and JIA show interesting results in terms of progression and severity of the disease and, despite a small sample size, the presence of these three isotypes has been associated with a worse prognosis.39,71

Recent studies establish associations between the immune response to citrullinated antigens and genetic predisposition taking account the HLA of patients with RA, the class II HLA shared epitope (HLA-DRB1*0401/*0404) and mutations in the PTPN22 gene. This partnership represents a greater relative risk of RA.72 However, other studies have not been able to establish an association between the shared epitope and the presence of anti-CCP. Patients with smoking and a genetic predisposition due to HLA-DRB1 present citrullinated proteins in broncho-alveolar cells in the bronchial lavage, which has been related to smoking as a triggering environmental factor to be taken into account in the multifactorial pathophysiology of RA.73 Another factor that should be considered as possibly triggering the abnormal formation of anti-CCP is the bacterial pathogen Porphyromonas gingivalis, an etiologic agent of bacterial gingivitis and epidemiologically linked to RA, which is capable of generating citrullinated antigens correlated with the development of RA.74

Several theories about the possibility of antigen presentation by immune system components, along with a failures in immunoregulation in genetically susceptible patients are discussed as a cause of developing a multifactorial syndrome such as RA.74 Contemplating the multifactorial pathogenesis of RA, perhaps we should try to more precisely identify the formation of anti-CCP as an important event, something that can help in the future to define profiles of patients who benefit from specific therapeutic lines.

Anti-CCP as a Factor of Poor Prognosis in Rheumatoid Arthritis

The search for biomarkers associated with response to biological and biological therapies has thus far been frustrating. Although clinical factors have been associated with remission in RA (male gender, older age of onset of illness, no smoking, low degree of initial disability as measured by HAQ, negative acute phase reactants or absence of RF and anti-CCP), none of them assures the success of our therapeutic actions.75

We know that the presence of IgA RF detected at the beginning of RA is associated with a worse prognosis and poorer response to biological therapy.55,76 The presence of both RF and anti-CCP antibody years before the development of clinical inflammation55 makes us objectify synovitis in our patients as just the consequence of activation of an wrong innate–adaptive immune response. Therefore, activity in the bone marrow and lymphoid organs secondary to antigen presentation and the development of a humoral response must have a certain importance.

Other factors related to remission are more dependent on medical intervention, as early treatment with non-biological disease modifying drugs leads to good or moderate responses in the first three to six months,10 and the early introduction of a biological agent leads to this objective.16

Even so, obtaining remission in our patients, beyond the concepts outlined above, remains purely random, not exceeding ACR 70 in more than 20% of patients.29 We do not know if this clinical remission is always accompanied by extraarticular, radiological, or much less immune remission.

Nevertheless, although RA is a multifactorial disease and we are still far from understanding the pathogenic cycle of each of our patients, optimizing the prognosis of patients, especially those at risk of progressing, is in our hands.

The presence of elevated anti-CCP and CRP, HAQ or erosive disease at the beginning of the disease, has been identified as a criterion of poor prognosis77–79; existing recommendations are based on not delaying treatment in these patients and not precisely emphasizing drug combinations with biologics.80 Recently, radiographic damage in RA in which an array of combinations of different factors, including so-called “poor prognosis” ones have been associated with the development of rapidly progressive radiological damage.81,82

The concept of step-down in patients with poor prognostic factors could be used in clinical practice taking into account the recommendations of the SER clinical guidelines, starting directly with a biological agent to induce early remission,27 further reducing doses83 or even discontinuating the treatment. The BeSt trial results and study shows that combining therapies with biological drugs and an early induction of remission in RA could lead to drug discontinuation and maintenance of remission in 12% and up to 30% of patients with RA.18,20,21

In this regard, recent studies in cohorts of patients with poor prognostic factors and no previous use of methotrexate (MTX) show that the results based on DAS 28, ACR 50, ACR 70 and HAQ undergoing early biological therapy are superior to those obtained with MTX alone. In this study, patients in an open phase receiving step up biological therapy showed improved results, but never became comparable with those in which biological treatment as was the initial option.84

It might be argued that although the levels of IgG anti-CCP are changed after the use of anti-TNF85 therapies,86 their concentrations do not relate directly to improvement or clinical relapse in all patients. Although controversial, it was noted that patients treated with monoclonal antibodies against the TNF-α molecule (adalimumab) significantly reduced their titers of IgG anti-CCP and were clinically responsive, reaching at least an ACR 20 response at 24 weeks.87

Highlighting humoral immune activity a priori, something “pathognomonic” in patients with RA, is interesting to evaluate different evidence that indicates that the RF and anti-CCP negativity are factors associated with better clinical outcome and better response to anti-TNF therapies.88,89 This is also associated to increased survival of anti-TNF drugs and clinical improvement in patients with “seronegative arthropathies”.90 Furthermore, the role of T lymphocytes91 as costimulators of B lymphocytes (CTL4Ig) has proven an effective therapeutic target in RA.6 Likewise, therapies directed to control B lymphocytes4 or antibody-forming plasma cells, such as inhibition of the IL-6 receptor (IL-6R)5 have also proven highly effective in RA. The impact of other therapeutic targets, beyond the inhibition of TNF-α has in the humoral response which mediates the production of anti citrullinated protein antibodies in RA is still undetermined. It is interesting to note that, unlike anti-TNF therapies, therapeutic targets related to B cell (anti-CD20, anti-IL-6R or CTL4Ig)92,93 have shown no utility in these other “seronegative diseases” so at least in part, their efficacy in RA patients could be attributed to an altered humoral response regulation.

Conclusions

It is possible that future studies demonstrate that induction of remission in early RA can help us step down and even suspend biological therapies to maintain remission and make them more cost effective. While not being completely accurate, biological use in all patients should be employed to manage at least in the early phase, those patients at risk for a worse prognosis.

The reality is that we are still far from offering therapeutic strategies tailored to patient profiles, although therapies are increasingly adapted to their clinical conditions and comorbidities. Even without understanding the pathophysiologic mechanism mediating the ability to generate antibodies against proteins and then develop more aggressive disease, the literature supports this as a determining factor in the poor outcome of our patients. The challenge is to understand how the different therapies that modulate humoral immunity go wrong, which could lead to a better understanding of factors associated with a worse outcome in our patients, improving the use of the therapeutic arsenal available to us today.

References
[1]
R. Maini, E.W. St Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, et al.
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study.
Lancet, 354 (1999), pp. 1932-1939
[2]
D. Van der Heijde, L. Klareskog, A. Singh, J. Tornero, J. Melo-Gomes, C. Codreanu, et al.
Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.
Ann Rheum Dis, 65 (2006), pp. 328-334
[3]
G.R. Burmester, X. Mariette, C. Montecucco, I. Monteagudo-Sáez, M. Malaise, A. Tzioufas, et al.
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.
Ann Rheum Dis, 66 (2007), pp. 732-739
[4]
P. Emery, R. Fleischmann, A. Filipowicz-Sosnowska, J. Schechtman, L. Szczepanski, A. Kavanaugh, et al.
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb double-blind, placebo-controlled, dose-ranging trial (DANCER).
Arthritis Rheum, 54 (2006), pp. 1390-1400
[5]
J.S. Smolen, A. Beaulieu, A. Rubbert-Roth, C. Ramos-Remus, J. Rovensky, et al.
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind placebo-controlled randomised trial.
[6]
J.M. Kremer, A.S. Russell, P. Emery, C. Abud-Mendoza, J. Szechinski, R. Westhovens, et al.
Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial.
Ann Rheum Dis, 70 (2011), pp. 1826-1830
[7]
S. Ramiro, A.M. Van Tubergen, R.B. Landewé.
RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid artritis.
Expert Rev Clin Immunol, 6 (2010), pp. 713-720
[8]
P. Emery, R.M. Fleischmann, L.W. Moreland, E.C. Hsia, I. Strusberg, P. Durez, et al.
Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
Arthritis Rheum, 60 (2009), pp. 2272-2283
[9]
J.S. Smolen, D. Aletaha, J.W. Bijlsma, F.C. Breedveld, D. Boumpas, G. Burmester, et al.
Treating rheumatoid arthritis to target: recommendations of an international task force.
Ann Rheum Dis, 69 (2010), pp. 631-637
[10]
B.H. Resman-Targoff, M.P. Cicero.
Aggressive treatment of early rheumatoid arthritis: recognizing the window of opportunity and treating to target goals.
Am J Manag Care, 16 (2010), pp. S249-S258
[11]
D. Aletaha, T. Neogi, A.J. Silman, J. Funovits, D.T. Felson, C.O. Bingham 3rd, et al.
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Ann Rheum Dis, 63 (2011), pp. 573-586
[12]
D.T. Felson, J.S. Smolen, G. Wells, B. Zhang, L.H. Van Tuyl, J. Funovits, et al.
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.
Arthritis Rheum, 63 (2011), pp. 573-586
[13]
Y.P. Goekoop-Ruiterman, J.K. De Vries-Bouwstra, C.F. Allaart, D. Van Zeben, P.J. Kerstens, J.M. Hazes, et al.
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Arthritis Rheum, 58 (2008), pp. S126-S135
[14]
L.G. Schipper, W. Kievit, A.A. Den Broeder, M.A. Van der Laar, E.M. Adang, J. Fransen, et al.
Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.
Rheumatology (Oxford), 50 (2011), pp. 1320-1330
[15]
H. Rezaei, S. Saevarsdottir, K. Forslind, K. Albertsson, H. Wallin, J. Bratt, et al.
In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial.
Ann Rheum Dis, 71 (2012), pp. 186-191
[16]
R.B. Landewé.
The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing.
Arthritis Rheum, 48 (2003), pp. 1-5
[17]
M. Dougados, M.P. Luo, W.P. Maksymowych, J.J. Chmiel, N. Chen, R.L. Wong, et al.
Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial.
Arthritis Rheum, 59 (2008), pp. 553-560
[18]
M.E. Weinblatt, J.M. Bathon, J.M. Kremer, R.M. Fleischmann, M.H. Schiff, R.W. Martin, et al.
Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and long-standing rheumatoid arthritis.
Arthritis Care Res (Hoboken), 63 (2011), pp. 373-382
[19]
D. Van der Heijde, F.C. Breedveld, A. Kavanaugh, E.C. Keystone, R. Landewé, K. Patra, et al.
Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER.
J Rheumatol, 37 (2010), pp. 2237-2246
[20]
N.B. Klarenbeek, M. Güler-Yüksel, S.M. Van der Kooij, K.H. Han, H.K. Ronday, P.J. Kerstens, et al.
The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.
Ann Rheum Dis, 70 (2011), pp. 1039-1046
[21]
F.C. Breedveld, M.H. Weisman, A.F. Kavanaugh, S.B. Cohen, K. Pavelka, R. Van Vollenhoven, et al.
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
Arthritis Rheum, 54 (2006), pp. 26-37
[22]
J.R. Kirwan.
Links between radiological change, disability, and pathology in rheumatoid arthritis.
J Rheumatol, 28 (2001), pp. 881-886
[23]
D. Aletaha, F. Alasti, J.S. Smolen.
Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression.
Ann Rheum Dis, 70 (2011), pp. 1975-1980
[24]
D. Van der Heijde, R. Landewé, R. Van Vollenhoven, S. Fatenejad, L. Klareskog.
Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial.
Ann Rheum Dis, 67 (2008), pp. 1267-1270
[25]
J.S. Smolen, F.C. Breedveld, M.H. Schiff, J.R. Kalden, P. Emery.
A simplified disease activity index for rheumatoid arthritis for use in clinical practice.
Rheumatology (Oxford), 42 (2003), pp. 244-257
[26]
D. Aletaha, J. Smolen.
The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid artritis.
Clin Exp Rheumatol, 23 (2005), pp. S100-S108
[27]
J.S. Smolen, D. Aletaha.
The assessment of disease activity in rheumatoid artritis.
Clin Exp Rheumatol, 28 (2010), pp. S18-S27
[28]
GUIPCAR 2011 [March 2011]. Available from: www.ser.es.
[29]
J.A. Singh.
Cyanoacrylate microbial sealants for skin preparation prior to surgery.
Cochrane Database of Syst Rev, 4 (2009), pp. CD007848
[30]
T.D. Jaskowski, H.R. Hill, K.L. Russo, G. Lakos, Z. Szekanecz, M. Teodorescu.
Relationship between rheumatoid factor isotypes and IgG anti-cyclic citrullinated peptide antibodies.
J Rheumatol, 37 (2010), pp. 1582-1588
[31]
W.J. Van Venrooij, J.J. Van Beers, G.J. Pruijn.
Anti-CCP antibodies: the past, the present and the future.
Nat Rev Rheumatol, 7 (2011), pp. 391-398
[32]
K. Forslind, M. Ahlmén, K. Eberhardt, I. Hafström, B. Svensson, BARFOT Study Group.
Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP).
Ann Rheum Dis, 63 (2004), pp. 1090-1095
[33]
S.M. Van der Kooij, Y.P. Goekoop-Ruiterman, J.K. De Vries-Bouwstra, M. Güler-Yüksel, A.H. Zwinderman, P.J. Kerstens, et al.
Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.
Ann Rheum Dis, 68 (2009), pp. 914-921
[34]
F.J. López-Longo, D. Oliver-Miñarro, I. De la Torre, E. González-Díaz de Rábago, S. Sánchez-Ramón, M. Rodríguez-Mahou, et al.
Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis.
Arthritis Rheum, 61 (2009), pp. 419-424
[35]
O.D. Ortega-Hernandez, R. Pineda-Tamayo, A.L. Pardo, A. Rojas-Villarraga, J.M. Anaya.
Cardiovascular disease is associated with extra-articular manifestations in patients with rheumatoid arthritis.
Clin Rheumatol, 28 (2009), pp. 767-775
[36]
O. Snir, M. Widhe, M. Hermansson, C. Von Spee, J. Lindberg, S. Hensen, et al.
Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients.
Arthritis Rheum, 62 (2010), pp. 44-52
[37]
E.R. Vossenaar, T.J. Smeets, M.C. Kraan, J.M. Raats, W.J. Van Venrooij, P.P. Tak.
The presence of citrullinated proteins is not specific for rheumatoid synovial tissue.
Arthritis Rheum, 50 (2004), pp. 3485-3494
[38]
A.W. Morgan, W. Thomson, S.G. Martin.
Yorkshire Early Arthritis Register Consortium, Carter AM; UK Rheumatoid Arthritis Genetics Consortium. Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population.
Arthritis Rheum, 60 (2009), pp. 2565-2576
[39]
K.N. Verpoort, C.M. Jol-van der Zijde, E.A.M. Papendrecht-van der Voort, A. Ioan-Facsinay, J.W. Drijfhout, M.J. Van Tol.
Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response.
Arthritis Rheum, 54 (2006), pp. 3799-3808
[40]
G.A. Schellekens, B.A. De Jong, F.H. Van den Hoogen, L.B.A. Van de Putte, W.J. Van Venrooij.
Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies.
J Clin Invest, 101 (1998), pp. 273-281
[41]
D.M. Lee, P.H. Schur.
Clinical utility of the anti-CCP assay in patients with rheumatic diseases.
Ann Rheum Dis, 62 (2003), pp. 870-874
[42]
T. Senshu, K. Akiyama, A. Ishigami.
Nomura Studies on specificity of peptidylarginine deiminase reactions using an immunochemical probe that recognizes an enzymatically deiminated partial sequence of mouse keratin K1.
J Dermatol Sci, 21 (1999), pp. 113-126
[43]
M.A. Moscarello, D.D. Wood, C. Ackerley, C. Boulias.
Myelin in multiple sclerosis is developmentally immature.
J Clin Invest, 94 (1994), pp. 146-154
[44]
D.D. Wood, J.M. Bilbao, P. O’Connors, M.A. Moscarello.
Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein.
Ann Neurol, 40 (1996), pp. 18-24
[45]
P.W. Wright, L.C. Bolling, M.E. Calvert, O.F. Sarmento, E.V. Berkeley, M.C. Shea, et al.
ePAD, an oocyte and early embryo-abundant peptidylarginine deiminase-like protein that localizes to egg cytoplasmic sheets.
Dev Biol, 256 (2003), pp. 73-88
[46]
H. Asaga, M. Yamada, T. Senshu.
Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages.
Biochem Biophys Res Commun, 243 (1998), pp. 641-646
[47]
M. Mizoguchi, M. Manabe, Y. Kawamura, Y. Kondo, K. Ishidoh, E. Kominami, et al.
Deimination of 70-kD nuclear protein during epidermal apoptotic events in vitro.
J Histochem Cytochem, 46 (1998), pp. 1303-1309
[48]
Y. Wang, J. Wysocka, J. Sayegh, Y.H. Lee, J.R. Perlin, L. Leonelli, et al.
Human PAD4 regulates histone arginine methylation levels via demethylimination.
Science, 306 (2004), pp. 279-283
[49]
G.L. Cuthbert, S. Daujat, A.W. Snowden, H. Erdjument-Bromage, T. Hagiwara, M. Yamada, et al.
Histone deimination antagonizes arginine methylation.
[50]
A. Suzuki, R. Yamada, X. Chang, S. Tokuhiro, T. Sawada, M. Suzuki, et al.
Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis.
Nat Genet, 34 (2003), pp. 395-402
[51]
J. Samuels, Y.S. Ng, C. Coupillaud, D. Paget, E. Meffre.
Human B cell tolerance and its failure in rheumatoid arthritis.
Ann N Y Acad Sci, 1062 (2005), pp. 116-126
[52]
H. Wardemann, S. Yurasov, A. Schaefer, J.W. Young, E. Meffre, M.C. Nussenzweig.
Predominant autoantibody production by early human B cell precursors.
Science, 301 (2003), pp. 1374-1377
[53]
J. Samuels, Y.S. Ng, C. Coupillaud, D. Paget, E. Meffre.
Impaired early B cell tolerance in patients with rheumatoid arthritis.
J Exp Med, 201 (2005), pp. 1659-1667
[54]
E. Roosnek, A. Lanzavecchia.
Efficient and selective presentation of antigen–antibody complexes by rheumatoid factor B cells.
J Exp Med, 173 (1991), pp. 487-489
[55]
S. Rantapaa-Dahlqvist, B.A.W. De Jong, E. Berglin, G. Hallmans, G. Wadell, H. Stenlund, et al.
Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.
Arthritis Rheum, 48 (2003), pp. 2741-2749
[56]
R.L. Nienhuis, E. Mandema.
A new serum factor in patients with rheumatoid arthritis: the antiperinuclear factor.
Ann Rheum Dis, 23 (1964), pp. 302-305
[57]
B.J. Young, R.K. Mallya, R.D. Leslie, C.J. Clark, T.J. Hamblin.
Antikeratin antibodies in rheumatoid arthritis.
Br Med J, 2 (1979), pp. 97-99
[58]
M. Sebbag, M. Simon, C. Vincent, C. Masson-Bessiere, E. Girbal, J.J. Durieux, et al.
The anti-perinuclear factor and the so-called anti-keratin antibodies are the same rheumatoid arthritis-specific autoantibodies.
J Clin Invest, 95 (1995), pp. 2672-2679
[59]
T. Senshu, G. Serre.
The major synovial targets of the rheumatoid arthritis-specific anti-filaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin.
J Immunol, 66 (2001), pp. 4177-4184
[60]
F.J. López-Longo, M. Rodríguez-Mahou, S. Sánchez-Ramón, A. Estecha, M. Balsera, R. Plaza, et al.
Anti-cyclic citrullinated peptide versus anti-Sa antibodies in diagnosis of rheumatoid arthritis in an outpatient clinic for connective tissue disease and spondyloarthritis.
J Rheumatol, 33 (2006), pp. 1476-1481
[61]
C. Anzilotti, F. Pratesi, C. Tommasi, P. Migliorini.
Peptidylarginine deiminase 4 and citrullination in health and disease.
Autoimmun Rev, 9 (2010), pp. 158-160
[62]
B. Gyorgy, E. Toth, E. Tarcsa, A. Falus, E.I. Buzas.
Citrullination: a posttranslational modification in health and disease.
Int J Biochem Cell Biol, 38 (2006), pp. 1662-1677
[63]
A. Ishigami, N. Maruyama.
Importance of research on peptidylarginine deiminase and citrullinated proteins in age-related disease.
Geriatr Gerontol Int, (2010), pp. S53-S58
[64]
E.R. Vossenaar, N. Després, E. Lapointe, A. Van der Heijden, M. Lora, T. Senshu, et al.
Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin.
Arthritis Res Ther, 6 (2004), pp. R142-R150
[65]
M. Rodríguez-Mahou, F.J. López-Longo, S. Sánchez-Ramón, A. Estecha, A. García-Segovia.
Association of anti-cyclic citrullinated peptide and anti-Sa/citrullinated vimentin autoantibodies in rheumatoid arthritis.
Arthritis Rheum, 55 (2006), pp. 657-661
[66]
L. Nogueira, M. Sebbag, C. Vincent, M. Arnaud, B. Fournie, A. Cantagrel, et al.
Performance of two ELISAs for antifilaggrin autoantibodies, using either affinity purified or deiminated recombinant human filaggrin, in the diagnosis of rheumatoid arthritis.
Ann Rheum Dis, 60 (2001), pp. 882-887
[67]
C. Vincent, L. Nogueira, M. Sebbag, S. Chapuy-Regaud, M. Arnaud, O. Letourneur, et al.
Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis.
Arthritis Rheum, 46 (2002), pp. 2051-2058
[68]
O. Snir, M. Widhe, M. Hermansson, C. Von Spee, J. Lindberg, S. Henson, et al.
Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients.
Ann Rheum Dis, 62 (2010), pp. 44-52
[69]
A. Kinloch, V. Tatzer, R. Wait, D. Peston, K. Lundberg, P. Donatien, et al.
Identification of citrullinated α-enolase as a candidate autoantigen in rheumatoid arthritis.
Arthritis Res Ther, 7 (2005), pp. R1421-R1429
[70]
H. Burkhardt, B. Sehnert, R. Bockermann, J.R. Kalden, R. Holmdahl.
Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis.
Eur J Immunol, 35 (2005), pp. 1643-1652
[71]
R.H. Syed, B.E. Gilliam, T.L. Moore.
Prevalence and significance of isotypes of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis.
Ann Rheum Dis, 67 (2008), pp. 1049-1051
[72]
E. Berglin, L. Padyukov, U. Sundin, G. Hallmans, H. Stenlund, W.J. Van Venrooij, et al.
A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis.
Arthritis Res Ther, 6 (2004), pp. R303-R308
[73]
K.N. Verpoort, E.A. Papendrecht-van der Voort, A.H. Van der Helm-van Mil, C.M. Jol-van der Zijde, M.J. Van Tol, J.W. Drijfhout, et al.
Association of smoking with the constitution of the anti-cyclic citrullinated peptide response in the absence of HLA-DRB1 shared epitope alleles.
Arthritis Rheum, 56 (2007), pp. 2913-2918
[74]
P. De Pablo, I.L.C. Chapple, C.D. Buckley, T. Dietrich.
Periodontitis in systemic rheumatic diseases.
Nat Rev Rheumatol, 5 (2009), pp. 218-224
[75]
W. Katchamart, S. Johnson, H.J. Lin, V. Phumethum, C. Salliot, C. Bombardier.
Predictors for remission in rheumatoid arthritis patients: a systematic review.
Arthritis Care Res (Hoboken), 62 (2010), pp. 1128-1243
[76]
F. Bobbio-Pallavicini, R. Caporali, C. Alpini, R. Moratti, C. Montecucco.
Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-alpha treated patients.
Ann N Y Acad Sci, 1109 (2007), pp. 287-295
[77]
J. Sokolove, X. Zhao, P.E. Chandra, W.H. Robinson.
Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcγ receptor.
Arthritis Rheum, 63 (2011), pp. 53-62
[78]
H. Maciejewska Rodrigues, A. Jüngel, R.E. Gay, S. Gay.
Innate immunity, epigenetics and autoimmunity in rheumatoid arthritis.
Mol Immunol, 47 (2009), pp. 12-18
[79]
R. Knevel, M. Schoels, T.W. Huizinga, D. Aletaha, G.R. Burmester.
Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.
Ann Rheum Dis, 69 (2010), pp. 987-994
[80]
K. Visser, Y.P. Goekoop-Ruiterman, J.K. De Vries-Bouwstra, H.K. Ronday, P.E. Seys, P.J. Kerstens, et al.
A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study.
Ann Rheum Dis, 69 (2010), pp. 1333-1337
[81]
N. Vsaeger, S. Xu, D. Aletaha, E.W. St Clair, J.S. Smolen.
A pilot risk model for the prediction of rapid radiographic progression in rheumatoid artritis.
Rheumatology (Oxford), 48 (2009), pp. 1114-1121
[82]
G. Kobelt, I. Lekander, A. Lang, B. Raffeiner, C. Botsios, P. Geborek.
Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment.
Int J Technol Assess Health Care, 27 (2011), pp. 193-200
[83]
J. Bathon, M. Robles, A.C. Ximenes, S. Nayiager, J. Wollenhaupt, P. Durez, et al.
Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes.
Ann Rheum Dis, 70 (2011), pp. 1949-1956
[84]
A. Bruns, P. Nicaise-Roland, G. Hayem, E. Palazzo, P. Dieudé, S. Grootenboer-Mignot, et al.
Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.
Joint Bone Spine, 76 (2009), pp. 248-253
[85]
H.A. Chen, K.C. Lin, C.H. Chen, H.T. Liao, H.P. Wang, H.N. Chang, et al.
The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
Ann Rheum Dis, 65 (2006), pp. 35-39
[86]
M. Cuchacovich, D. Catalan, E. Wainstein, H. Gatica, L. Soto, O. Aravena, et al.
Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis.
Clin Exp Rheumatol, 26 (2008), pp. 1067-1073
[87]
L. Mancarella, F. Bobbio-Pallavicini, F. Ceccarelli, P.C. Falappone, A. Ferrante, D. Malesci, et al.
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
J Rheumatol, 34 (2007), pp. 1670-1673
[88]
C. Potter, K.L. Hyrich, A. Tracey, M. Lunt, D. Plant, D.P. Symmons, et al.
Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.
Ann Rheum Dis, 68 (2009), pp. 69-74
[89]
M.S. Heiberg, B.Y. Nordvåg, K. Mikkelsen, E. Rødevand, C. Kaufmann, P. Mowinckel, et al.
The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
Arthritis Rheum, 52 (2005), pp. 2506-2512
[90]
J.D. Isaacs.
Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future.
Rheumatology (Oxford), 47 (2008), pp. 1461-1468
[91]
I.H. Song, F. Heldmann, M. Rudwaleit, H. Haibel, A. Weiss, J. Braun, et al.
Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study.
Ann Rheum Dis, 70 (2011), pp. 1108-1110
[92]
D. Baeten, E. Kruithof, M. Breban, P.P. Tak.
Spondylarthritis in the absence of B lymphocytes.
Arthritis Rheum, 58 (2008), pp. 730-733
[93]
J.C. Henes, M. Horger, I. Guenaydin, L. Kanz, I. Koetter.
Mixed response to tocilizumab for ankylosing spondylitis.
Ann Rheum Dis, 69 (2010), pp. 2217-2218

Please, cite this article as: Valor L, De la Torre Ortega I. ¿Debemos usar los factores de mal pronóstico para iniciar precozmente un tratamiento biológico en los pacientes con artritis reumatoide? Reumatol Clin. 2012;8:163–7.

Copyright © 2011. Elsevier España, S.L.. All rights reserved
Idiomas
Reumatología Clínica (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.